Boston Scientific Corporation
BSX
$106.13
-$0.265-0.25%
NYSE
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 8.54% | 2.24% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 8.54% | 2.24% | |||
| Cost of Revenue | 12.54% | -0.54% | |||
| Gross Profit | 6.70% | 3.56% | |||
| SG&A Expenses | 7.45% | -0.93% | |||
| Depreciation & Amortization | 2.74% | -2.67% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.52% | -1.19% | |||
| Operating Income | 0.64% | 18.61% | |||
| Income Before Tax | 16.89% | 37.61% | |||
| Income Tax Expenses | 9.77% | 478.26% | |||
| Earnings from Continuing Operations | 18.30% | 19.57% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 0.00% | -50.00% | |||
| Net Income | 18.25% | 19.08% | |||
| EBIT | 0.64% | 18.61% | |||
| EBITDA | 1.35% | 10.90% | |||
| EPS Basic | 18.01% | 19.05% | |||
| Normalized Basic EPS | 55.64% | 8.25% | |||
| EPS Diluted | 17.78% | 18.51% | |||
| Normalized Diluted EPS | 55.91% | 8.25% | |||
| Average Basic Shares Outstanding | 0.18% | 0.20% | |||
| Average Diluted Shares Outstanding | 0.03% | 0.19% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||